New therapeutics and breast cancer: signal transduction inhibitors

被引：0
作者：
Campone, M. [1 ]
机构：
[1] CLCC Rene Gauducheau, Inst Reg Cancerol Nantes Atlantique, Dept Med Oncol, F-44805 Nantes, France
来源：
ONCOLOGIE | 2007年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S33 / S40
页数：8
相关论文
共 51 条
[1]  
Albain K, 2002, BREAST CANCER RES TR, V76, pS33
[2]   Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer [J].
Allen, LF ;
Lenehan, PF ;
Eiseman, IA ;
Elliott, WL ;
Fry, DW .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :11-21
[3]   HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer [J].
Arteaga, CL ;
Moulder, SL ;
Yakes, FM .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :4-10
[4]  
BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13
[5]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[6]  
Baselga J, 1998, CANCER RES, V58, P2825
[7]  
BASELGA J, 2005, BREAST CANC RES TR S, V1, P1068
[8]  
BASELGA J, 2003, P AN M AM SOC CLIN, V22, P7
[9]   Phosphoinositide 3-kinase inhibition in cancer treatment [J].
Berrie, CP .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (06) :1085-1098
[10]  
BURSTEIN HJ, 2000, BREAST CANC RES TREA, V76, P446
123456